Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World study examines Isavuconazole's effectiveness against deadly fungal infections

NCT ID NCT04550936

Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at medical records of 307 adults in five European countries who were treated with the antifungal drug isavuconazole for serious fungal infections (invasive aspergillosis or mucormycosis). Researchers tracked how well the drug worked (clinical, radiological, and lab responses) and any side effects over 24 weeks. Since this was an observational study, patients received standard care as decided by their doctors, and no extra drugs were provided.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Isavuconazole (Cresemba)
What this could lead to
If the results confirm isavuconazole is effective and safe in routine care, it could reinforce its use as a treatment option for these serious fungal infections.
What could go wrong
This is an observational study, not a controlled trial, so it can't prove cause and effect. The results may be influenced by differences in patient care and underlying health conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

307 people

The number who actually took part.

Started

Mar 2021

Finished

Dec 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients who received isavuconazole for the treatment of invasive aspergillosis or mucormycosis in the hospital setting in five European countries (France, Germany, Italy, Spain, and the United Kingdom).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Hospitalized patient must be aged ≥ 18 years at the time of isavuconazole initiation 2. Patient must have a record of a diagnosis of invasive aspergillosis or mucormycosis in their medical record at the time isavuconazole was initiated (regardless of whether this diagnosis is suspected or confirmed ) 3. Patient must have received at least one dose of isavuconazole during the eligibility period (October 15, 2015, to June 30, 2019) Exclusion Criteria: 1\. Patients who did not receive at least one dose of isavuconazole for treatment of invasive aspergillosis or mucormycosis within the eligibility period

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Invasive aspergillosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

invasive aspergillosis Zygomycosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Invasive aspergillosis Mucormycosis

Contacts and locations

Locations

  • Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino

    Turin, Piedmont, 10126, Italy

  • CHU de Limoges

    Limoges, 87042, France

  • Cambridge University Hospitals NHS Foundation Trust

    Cambridge, CB2 0QQ, United Kingdom

  • Comprehensive Cancer Center Ulm (CCCU)

    Ulm, 89081, Germany

  • Fundació Clínic Per A La Recerca Biomèdica

    Barcelona, 08036, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

  • Hospital Universitario Marques de Valdecilla

    Santander, 39011, Spain

  • Institut de Cancérologie

    Strasbourg, 67033, France

  • King'S College Hospital Nhs Foundation Trust

    London, SE5 9RS, United Kingdom

  • Klinikum rechts der Isar Technische Universität München

    Munich, 81675, Germany

  • Paris University

    Paris, 75015, France

  • University Hospital Miguel Servet

    Zaragoza, 50009, Spain

  • University Hospital of Cologne

    Cologne, 50937, Germany

  • Universitätsklinik Frankfurt

    Frankfurt, 60590, Germany

  • Vall d'Hebron University Hospital

    Barcelona, 08035, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.